Roberta Vezza Alexander, PharmD, PhD. Associate Vice President, Clinical Research at Exagen Inc.

Roberta Vezza Alexander, PharmD, PhD

Associate Vice President, Clinical Research at Exagen Inc.

Dr. Alexander is the Associate Vice President, Clinical Research at Exagen where she oversees the design of clinical studies to demonstrate the clinical validity and utility of the AVISE test portfolio. She also oversees investigator-initiated studies and collaborations with pharmaceutical companies. Dr. Alexander has authored numerous publications in peer-reviewed journals and has presented abstracts at international conferences, including the annual meetings of the American College of Rheumatology (ACR). In addition, she has published two reviews on cell-bound complement activation products (CB-CAPs) in collaboration with leading lupologists in the USA.

Roberta Vezza Alexander holds a PharmD and a PhD from Universita’ degli Studi di Perugia in Italy and completed her post-doctoral fellowship at the School of Medicine of the University of Pennsylvania in Philadelphia. Dr. Alexander worked in drug discovery prior to entering the diagnostic laboratory space.


Doctorate Degree: Universita’ degli Studi di Perugia

PharmD: Universita’ degli Studi di Perugia

Fellowship: School of Medicine of the University of Pennsylvania in Philadelphia

Selected Publications

Sciascia S, Bloch R, O'Malley T, Kammesheidt A, Alexander RV. Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d. Front Immunol. 2022 Aug 10;13:949919. doi: 10.3389/fimmu.2022.949919. PMID: 36032074; PMCID: PMC9399821.

Alexander RV, Rey DS, Conklin J, Domingues V, Ahmed M, Qureshi J, Weinstein A. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. Lupus Sci Med. 2021 Jul;8(1):e000528. doi: 10.1136/lupus-2021-000528. PMID: 34253650; PMCID: PMC8276296.

Ramsey-Goldman R, Alexander RV, Conklin J, Arriens C, Narain S, Massarotti EM, Wallace DJ, Collins CE, Saxena A, Putterman C, Brady K, Kalunian KC, Weinstein A. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. ACR Open Rheumatol. 2021 Feb;3(2):116-123. doi: 10.1002/acr2.11219. Epub 2021 Feb 4. PMID: 33538130; PMCID: PMC7882535.

Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25. PMID: 31469249; PMCID: PMC6972605.

Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 Apr;7(1):e000377. doi: 10.1136/lupus-2019-000377. PMID: 32371480; PMCID: PMC7228655.

Dervieux T, Conklin J, Ligayon JA, Wolover L, O'Malley T, Alexander RV, Weinstein A, Ibarra CA. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. J Immunol Methods. 2017 Jul;446:54-59. doi: 10.1016/j.jim.2017.04.001. Epub 2017 Apr 5. PMID: 28389175.

Mossell J, Goldman JA, Barken D, Alexander RV. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Open Rheumatol J. 2016 Oct 31;10:71-80. doi: 10.2174/1874312901610010071. PMID: 27867431; PMCID: PMC5101629.

About Our Medical Review Process

Exagen content contributors bring extensive experience from lupus and autoimmune disease testing research to ensure our readers receive high-quality and safe health information.

Exagen articles are medically reviewed and medically fact-checked by rheumatology and autoimmune testing specialists to ensure that all factual statements about medical conditions, symptoms, procedures, tests, and standards of care are accurate and reflect current guidelines as well as the latest research. All topics are updated as new evidence becomes available and our editorial review process is complete.